147 related articles for article (PubMed ID: 18500432)
21. Antinuclear antibody positive autoimmune disorders in North India: an appraisal.
Minz RW; Kumar Y; Anand S; Singh S; Bamberi P; Verma S; Shegal S
Rheumatol Int; 2012 Sep; 32(9):2883-8. PubMed ID: 21898056
[TBL] [Abstract][Full Text] [Related]
22. The clinical relevance of antinuclear antibodies in connective tissue diseases.
Bombardieri S; Neri R; Tartarelli G; d'Ascanio A; Giovanelli L
Scand J Rheumatol Suppl; 1987; 66():35-45. PubMed ID: 3502510
[TBL] [Abstract][Full Text] [Related]
23. [Prevalence and diagnostic value of antinuclear antibodies without identified antigenic target: a retrospective study of 90 patients].
Feki S; Frikha F; Ben Hadj Hmida Y; Abed S; Ben Ayed M; Turki H; Hachicha J; Baklouti S; Bahloul Z; Masmoudi H
Rev Med Interne; 2012 Sep; 33(9):475-81. PubMed ID: 22658165
[TBL] [Abstract][Full Text] [Related]
24. [Comparison of indirect immunofluorescence and enzyme immunoassay methods for the determination of antinuclear antibodies].
Yilmaz O; Karaman M; Ergon MC; Bahar IH; Yuluğ N
Mikrobiyol Bul; 2004; 38(1-2):85-90. PubMed ID: 15293906
[TBL] [Abstract][Full Text] [Related]
25. The clinical significance of borderline results of the Elia CTD Screen assay.
Robier C; Amouzadeh-Ghadikolai O
Clin Chem Lab Med; 2018 Nov; 56(12):2088-2092. PubMed ID: 30032128
[TBL] [Abstract][Full Text] [Related]
26. Antinuclear antibodies and connective tissue disease features in fibromyalgia syndrome: a controlled study.
Yunus MB; Hussey FX; Aldag JC
J Rheumatol; 1993 Sep; 20(9):1557-60. PubMed ID: 8164214
[TBL] [Abstract][Full Text] [Related]
27. Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting.
Kallenberg CG; Wouda AA; Hoet MH; van Venrooij WJ
Ann Rheum Dis; 1988 Aug; 47(8):634-41. PubMed ID: 3261966
[TBL] [Abstract][Full Text] [Related]
28. The clinical utility of a positive antinuclear antibody test result.
Abeles AM; Abeles M
Am J Med; 2013 Apr; 126(4):342-8. PubMed ID: 23395534
[TBL] [Abstract][Full Text] [Related]
29. [Antinuclear antibodies, patterns and characteristics obtained by immunofluorescence. The importance of the IgA, IgM and IgG isotypes].
Arcavi M; Dadone J
Medicina (B Aires); 2009; 69(5):502-6. PubMed ID: 19897433
[TBL] [Abstract][Full Text] [Related]
30. Raynaud's phenomenon together with antinuclear antibodies: a common subset of incomplete connective tissue disease.
Vayssairat M; Baudot N; Gaitz JP
J Am Acad Dermatol; 1995 May; 32(5 Pt 1):747-9. PubMed ID: 7722019
[TBL] [Abstract][Full Text] [Related]
31. Early detection of connective tissue disease in patients with Raynaud's phenomenon.
Kallenberg CG
Rheum Dis Clin North Am; 1990 Feb; 16(1):11-30. PubMed ID: 2406802
[TBL] [Abstract][Full Text] [Related]
32. The predictive value of antinuclear antibodies in patients with suspected connective tissue disease for the development of connective tissue diseases.
Brunekreef TE; van den Heuvel HB; Limper M; Leavis H; van Laar JM; Otten H
Clin Exp Rheumatol; 2024 Jan; 42(1):24-29. PubMed ID: 38079340
[TBL] [Abstract][Full Text] [Related]
33. The role of endothelin-1 and selected cytokines in the pathogenesis of Raynaud's phenomenon associated with systemic connective tissue diseases.
Rychlik-Golema W; Mastej K; Adamiec R
Int Angiol; 2006 Jun; 25(2):221-7. PubMed ID: 16763543
[TBL] [Abstract][Full Text] [Related]
34. Clinical utility of antinuclear antibody tests in children.
McGhee JL; Kickingbird LM; Jarvis JN
BMC Pediatr; 2004 Jul; 4():13. PubMed ID: 15245579
[TBL] [Abstract][Full Text] [Related]
35. Use of panel testing for detection of antinuclear antibody in a resource-limited setting: an appraisal.
Minz RW; Kumar Y; Saikia B; Anand S; Varma S; Singh S
Postgrad Med; 2016 Nov; 128(8):869-874. PubMed ID: 27494797
[TBL] [Abstract][Full Text] [Related]
36. [Performance and clinical evaluation of antinuclear antibody test based on fluorescence enzyme immunoassay].
Watanabe N; Nagatomo R; Okubo S; Yokota H; Ikeda H; Yatomi Y
Rinsho Byori; 2014 Apr; 62(4):315-23. PubMed ID: 25022060
[TBL] [Abstract][Full Text] [Related]
37. Association between antinuclear antibody titers and connective tissue diseases in a Rheumatology Department.
Menor Almagro R; Rodríguez Gutiérrez JF; Martín-Martínez MA; Rodríguez Valls MJ; Aranda Valera C; de la Iglesia Salgado JL
Reumatol Clin; 2017; 13(3):150-155. PubMed ID: 27221374
[TBL] [Abstract][Full Text] [Related]
38. Antinuclear antibodies in children: clinical signification and diagnosis utility.
Mejdoub S; Hachicha H; Gargouri L; Feki S; Mahfoudh A; Masmoudi H
Tunis Med; 2021 Octobre; 99(10):980-984. PubMed ID: 35288899
[TBL] [Abstract][Full Text] [Related]
39. Performance of antinuclear antibody connective tissue disease screen.
López-Hoyos M; Rodríguez-Valverde V; Martinez-Taboada V
Ann N Y Acad Sci; 2007 Aug; 1109():322-9. PubMed ID: 17785321
[TBL] [Abstract][Full Text] [Related]
40. Undifferentiated connective tissue disease and interstitial lung disease: Trying to define patterns.
Alberti ML; Paulin F; Toledo HM; Fernández ME; Caro FM; Rojas-Serrano J; Mejía ME
Reumatol Clin (Engl Ed); 2018; 14(2):75-80. PubMed ID: 27979657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
